These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 30985048

  • 1. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.
    Kabbani D, Hirji A, Hernandez C, Malhi H, Mabilangan C, Chandrarathne S, Halloran K, Weinkauf J, Kapasi A, Lien D, Preiksaitis J, Cervera C.
    Transpl Infect Dis; 2019 Aug; 21(4):e13094. PubMed ID: 30985048
    [Abstract] [Full Text] [Related]

  • 2. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 16; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

  • 6. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S, Sullivan T, Ali M, Dunn D, Patel G, Huprikar S.
    Liver Transpl; 2018 May 16; 24(5):616-622. PubMed ID: 29500912
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, Husain S, Paterson DL, Chiller T, Pappas P.
    Transpl Infect Dis; 2018 Jun 16; 20(3):e12877. PubMed ID: 29512935
    [Abstract] [Full Text] [Related]

  • 8. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N, Koutsokera A, Pasquier J, Mombelli M, Meylan P, Pascual M, Aubert JD, Manuel O.
    Transpl Infect Dis; 2018 Aug 27; 20(4):e12893. PubMed ID: 29603543
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
    Rea F, Potena L, Yonan N, Wagner F, Calabrese F.
    Transplantation; 2016 Mar 15; 100 Suppl 3(Suppl 3):S19-26. PubMed ID: 26900991
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec 15; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 17. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Dec 15; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 18. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
    Low CY, Hosseini-Moghaddam SM, Rotstein C, Renner EL, Husain S.
    Transpl Infect Dis; 2017 Oct 15; 19(5):. PubMed ID: 28613442
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.